Document is current
Any future updates will be listed below
-
Authors
Batista-Liz, Joao Carlos
Calvo-Río, Vanesa
Mora-Gil, María Sebastián
Leonardo, María Teresa
Peñalba, Ana Cristina
Martín-Penagos, Luis
Narváez, Javier
Sevilla-Pérez, Belén
Callejas-Rubio, José Luis
Gabrie, Ligia
Sánchez, Rafael Gálvez
Caminal-Montero, Luis
Collado, Paz
Valls, María José Rodríguez
de Argila, Diego
Quiroga-Colina, Patricia
Vicente-Rabaneda, Esther Francisca
Rubio, Esteban
Luque, Manuel León
Blanco-Madrigal, Juan María
Galíndez-Agirregoikoa, Eva
Blanco, Ricardo
Pulito-Cueto, Verónica
López-Mejías, Raquel
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (FI22/00020, CPII21/00004)
Instituto de Investigación Marqués de Valdecilla (NVAL2302)
- License Information
-
More Information
Article History
Received: 19 February 2025
Accepted: 24 June 2025
First Online: 27 July 2025
Declarations
:
: All the patients diagnosed with IgAV, and healthy controls gave written informed consent before their inclusion in our study. Likewise, methods were carried out following the ethical standards of the approved guidelines and regulations, according to the Declaration of Helsinki, and the study was also approved by the Clinical Research Ethics Committee of Cantabria, Spain (protocol code 15/2012).
: Not applicable.
: The authors declare no competing interests.
